FDA Panel Says Benefits of J&J (JNJ) Birth Control Patch Outweigh Risks -Bloomberg
Tweet
Share
E-mailGet Alerts JNJ Hot Sheet
Join SI Premium – FREE
Bloomberg reporting: an FDA panel has voted 19-5 benefits of J&J's (NYSE: JNJ) birth control patch outweigh risks.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA: issues early alert on Abiomed heart pump controller purge cassette issue
- BioNTech ends colorectal cancer mRNA therapy trial early
- FDA clears Adicet Bio IND application for prostate cancer therapy
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
